Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Ebola Outbreak The World Health Organization (WHO) is supporting the PARTNERS trial, which compares treatment options for Bundibugyo virus disease without discontinuing standard medical care. A separate team at the University of Oxford has begun an early trial of a candidate vaccine in volunteers. By August 17, epidemiologist Devi Sridhar wrote in a column for The Guardian that the outbreak in the Democratic Republic of Congo had reached an estimated 4,900 cases and over 2,300 deaths. The WHO-backed PARTNERS trial randomly assigns patients with confirmed Bundibugyo disease to different antiviral treatment options. In the Democratic Republic of Congo, it is coordinated by the National Institute of Biomedical Research (INRB), a research center of the country's Ministry of Health. All participants receive standard medical care and are monitored for at least 28 days, allowing researchers to compare which treatment regimen is more effective in helping patients survive. The vaccine is being tested separately: on July 24, the first volunteer at the University of Oxford received the ChAdOx1 BDBV candidate vaccine against Bundibugyo. In the first phase, the team is checking its safety and immune response in volunteers, while the treatment is being studied in patients in the outbreak zone, as reported in The Guardian, August 2023. The possibility of including a patient in the trial depends on how quickly they reach medical help, according to Nature Aging, July 2026. 🔗 Read original →